AMOEBA (EPA:ALMIB) - AMOEBA: Modalities through which the preparatory documents will be made available / General Meeting to be held on 24 June 2021

Transparency directive : regulatory news

02/06/2021 17:45

PRESS RELEASE

Chassieu, 02 june 2021

     ORDINARY AND EXTRAORDINARY GENERAL MEETING TO BE HELD ON 24 JUNE 2021

   MODALITIES THROUGH WHICH THE PREPARATORY DOCUMENTS WILL BE MADE AVAILABLE

The General Meeting of Amoéba shareholders, convened on May 27, 2021 at 9 a.m.
at the Company's registered office, did not reach the quorum required to vote
on the ordinary and extraordinary resolutions.

Consequently, a new Ordinary and Extraordinary Shareholders' Meeting will be
held on second call on:

                      Thursday 24 June 2021 - 9.00 am
     at the company registered office - 38 Avenue des Frères Montgolfier -
                              69680 CHASSIEU

for the purpose of ruling on the same agenda as the first convocation notice,
published in the Bulletin des Annonces Légales Obligatoires (BALO) of 10 may
2021.

The notice of the second convocation including the agenda was published in the
Bulletin des Annonces légales Obligatoires (BALO) of June 2, 2021. The terms
and conditions of participation and voting at the Meeting are set out in this
notice.

The documents stipulated by article R.225-83 of the French commercial code are
available to shareholders from the moment that the assembly is convened, in
line with the applicable regulatory requirements:

  * Any registered shareholder can, until the fifth day (inclusive) before the
    assembly, ask the company to send him these documents. For holders of
    bearer shares, this right can only be exercised upon presentation of a
    statement of participation in the accounts of bearer shares held by the
    authorised intermediary;

  * Any shareholder can consult these documents at the company's headquarters
    during the 15 days preceding the date of the meeting.

                                     REMINDER
                      VOTE DIRECTLY ONLINE USING VOTACCESS

As of today, Wednesday, June 2, log on to the website of your financial
intermediary dedicated to the management of your AMOEBA shares, with your usual
access codes and vote online if you hold your shares in one of the following
banks (list of banks offering access to the VOTACESS platform): Banque
Populaire, Banque Postale, BNP Paribas, Bourse Direct, Boursorama, Caisse
d'Epargne, Crédit Agricole, Crédit Mutuel, CIC, HSBC, Milleis, Natixis,
Société Générale.

NEED MORE INFORMATION?

Find all the information you need to vote by post or give proxy to the Chairman
on our dedicated page:
https://amoeba-nature.com/en/investor/general-assembly/

We are at your disposal to provide you with any additional information on
voting procedures by calling+ 33 (0)1 53 65 68 68 or by email at
amoeba@calyptus.net

Disclaimer

In the context of the coronavirus epidemic (COVID-19), the procedures for
holding the Shareholders'
Meeting may change depending on health and/or legal requirements. Shareholders
are invited to regularly consult the section dedicated to the Shareholders'
Meeting on the Company's website
(http://www.amoeba-nature.com/Investors/General-assembly).

About AMOEBA:
Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.
Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on Euronext Growth. The Company is
a member of the BPIfrance Excellence network and is eligible for the PEA-PME
SME equity savings plan setup. More information on www.amoeba-nature.com.

(1) : Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2) : Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies,"
Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts: Amoéba
Valérie FILIATRE
Directeur Général Adjoint
+33 4 26 69 16 00
v.filiatre@amoeba-nature.com

Calyptus
Relations investisseurs & Presse
Grégory BOSSON / Mathieu CALLEUX
+33 1 53 65 37 90 /91
amoeba@calyptus.net

Adresse : 38 Avenue des Frères Montgolfier, 69680 CHASSIEU
Société Anonyme au capital de 341 109,20 EUR
RCS Lyon 523 877 215

Tel: +33 (0)4 26 69 16 00 ? Email: contact@amoeba-nature.com
Linkedin: @amoeba-nature ? Twitter: @AmoebaNature
www.amoeba-nature.com

AMOEBA's latest news

02/05/2024 18:00

AMOEBA (EPA:ALMIB) - AMOEBA: Modalities through which the preparatory documents will be made available / General Meeting to be held on 24 June 2021

Transparency directive : regulatory news

AMOEBA's latest news

Other stories